Nm. Heddle et al., THE ROLE OF THE PLASMA FROM PLATELET CONCENTRATES IN TRANSFUSION REACTIONS, The New England journal of medicine, 331(10), 1994, pp. 625-628
Background. Febrile, nonhemolytic transfusion reactions are the most f
requent adverse reactions to platelets. A number of observations argue
against the widely held view that these reactions result from the int
eraction between antileukocyte antibodies in the recipient and leukocy
tes in the platelet product. We sought to determine whether substances
in the plasma or the cells in the product cause reactions to transfus
ed platelets. Methods. We separated standard platelet concentrates int
o their plasma and cellular components and then transfused both portio
ns in random order. Patients were monitored for reactions during all t
ransfusions. Before each transfusion, the concentration of cytokines (
interleukin-1 beta and interleukin-6) was measured in the platelet pro
ducts. Studies were also performed on the platelet products to determi
ne the effect of storage on the concentration of cytokines. Results. S
ixty-four pairs of platelet-product components (the plasma supernatant
and the cells) were administered to 12 patients. There were 20 reacti
ons to the plasma supernatant and 6 reactions to the cells (chi-square
= 6.50, P = 0.009). Eight transfusions were associated with reactions
to both products. The plasma component was more likely to cause sever
e reactions than the cells (chi-square = 9.6, P < 0.01). A strong posi
tive correlation was observed between the reactions and the concentrat
ion of interleukin-1 beta and interleukin-6 in the plasma supernatant
(P < 0.001 and P = 0.034, respectively). In vitro studies demonstrated
that interleukin-1 beta and interleukin-6 concentrations rise progres
sively in stored platelets and that these concentrations are related t
o the leukocyte count in the platelet product. Conclusions. Bioreactiv
e substances in the plasma supernatant of the platelet product cause m
ost febrile reactions associated with platelet transfusions. Removing
the plasma supernatant before transfusion can minimize or prevent thes
e reactions.